Kasim Kutay is chief executive officer of Novo Holdings A/S, Denmark.
From 2009 to 2016 Mr Kutay was managing director, co-head of Europe and member of the Global Management Committee of Moelis & Co., UK. From 2007 to 2009 Mr Kutay was managing director and head of Financial Solutions Group of SUN Group, UK. From 1989 to 2007 Mr Kutay held a number of positions at Morgan Stanley, UK, including chair of the European Healthcare Group. Mr Kutay was member of the Board of Trustees of Northwick Park Institute for Medical Research, UK, from 2005 to 2016. Mr Kutay was member of the Board of Governors from 2006 to 2011 and the Investment Committee from 2011 to 2016 of the School of Oriental and African Studies (SOAS), UK.
Mr Kutay is member of the board of Novozymes A/S, Denmark, and of the Life Sciences Advisory Board of Gimv NV, Belgium.
Mr Kutay holds a B.Sc. in Economics and an M.Sc. in Economics, both from the London School of Economics, UK.
Mr Kutay was first elected to the Board of Novo Nordisk A/S in March 2017 and has most recently been re-elected in March 2019. His term as a board member expires in March 2020.
In March 2019, the Board of Directors of Novo Nordisk A/S assessed that Mr Kutay is not regarded as an independent board member as defined in Section 3.2.1 of the Danish Recommendations on Corporate Governance designated by Nasdaq Copenhagen due to Mr Kutay being the chief executive officer of Novo Holdings A/S.
Mr Kutay became a member of the Nomination Committee at Novo Nordisk A/S in March 2017.
In January 2019, the Board of Directors assessed that the special competences possessed by Mr Kutay that are important for the performance of his duties are his extensive experience as financial advisor to the pharmaceutical, biotechnology and medical device industries. Further, Mr Kutay has advised healthcare companies on an international basis including companies based in Europe, the USA, Japan and India.
Mr Kutay is a male UK national, born May 1965.